



Harrington Rare Disease Scholar Award Program Sponsored by Takeda

Request for Proposals

New Program Seeks to Accelerate the Development of Cures and Therapies for Rare Diseases

Letter of Intent Deadline: July 19, 2017
Full Application Deadline: October 4, 2017

Submit application online at HarringtonDiscovery.SmartSimple.com

The Harrington Rare Disease Scholar Award Program sponsored by Takeda aims to accelerate breakthrough research in rare diseases. The award recognizes MD and PhD researchers from across the United States whose discoveries show promise for translation into novel treatments and cures.

Up to 10 Harrington Rare Disease Scholars will be selected. Awardees are selected by Harrington Discovery Institute's Scientific Advisory Board for Rare Diseases.

Multi-Level Support for Award Recipients Includes:

- **\$150,000 guaranteed**; potential award of **up to \$1,000,000**
- **Drug development and project management support** through Harrington Discovery Institute's [Innovation Support Center](#)
- **Facilitated access to Takeda's research and development experts**
- Dedicated pharma team provided for each scholar
- Business and commercialization assessment
- Clinical development strategy
- Regulatory guidance
- Intellectual property review and strategy
- Access to contract research organizations/service providers

What We Fund



The selection committee for the Harrington Rare Disease Scholar Award Program sponsored by Takeda seeks breakthrough discoveries defined by innovation, creativity, and potential clinical impact including:

- Discoveries deemed to address unmet medical needs
- Modulators of novel and/or druggable targets
- Potential to be developed into a commercial program
- Strong intellectual property (IP) or protection strategy
- Small molecule, peptides, or biologics

Eligibility Criteria

- **Academic investigators** on faculty at accredited medical centers, research institutions, and universities in the **United States only**
- Lead investigator must have an MD and/or PhD (or equivalent)
- Past recipients of Harrington Scholar awards may submit new and distinct proposals, but may not seek additional support for previously funded projects

Areas of Interest

Our current target areas of interest include all rare diseases, but of particular interest are rare diseases in the **areas of neurology and gastroenterology**. Projects in the area of rare cancers will be considered on a case-by-case basis.

Submission Process

All applications must be submitted online at HarringtonDiscovery.SmartSimple.com.

Submission Instructions

- Please submit your application through HarringtonDiscovery.SmartSimple.com.
- Click "Register Here" button and complete applicant registration and log in to your account. If you are a past applicant, click "Forgot Password" to be emailed a temporary password.
- When you have logged in, click "My Profile" to input or update your contact information.
- Click the "Home" button to return to the homepage, and click on the "Apply Now" button to complete and submit your Letter of Intent.



Deadlines

Letter of Intent: July 19, 2017

For those invited, full application: October 4, 2017

Letter of Intent Outline

- **Stage of Development**
- **Primary Therapeutic Area and Primary Disease Focus of Proposed Research**
- **Target** – If known, please identify and describe the drug target of your project (**max 100 words**)
- **Project Title**
- **Abstract (public)** – Provide a non-confidential summary of the project including unmet medical need, disease mechanism, target pathway, proposed research, and validation (**max 250 words**)
- **Aims and Research Plan** – List goals and describe the research plan for the proposed project (**max 250 words**)
- **Impact** – Describe the potential clinical, medical impact, and/or commercial opportunity of the research project (**max 250 words**)
- **Novelty of Target or Product** – Describe the discovery, molecular target, and/or envisioned product and identify the critical product development unknowns or needs (e.g. target validation, lead discovery/optimization, safety/pharmacology, efficacy, etc.) (**max 250 words**)
- **Intellectual Property (IP)** – List relevant issued patents or published patent applications. Please mention if the IP is owned by you/your institution or co-owned with other institution(s) or for-profit third party (**max 250 words**)
- **Industry Relationships** – Identify any previous, active, or pending industry relationships related to the proposed project (**max 250 words**)
- **Biosketch** – Upload biosketch in NIH format for the Principal Investigator (**PDF only**)
- **Key Supporting Data (optional)** – Upload no more than one piece of key data that supports your proposal (**1 page limit, PDF only**)
- **References (optional)** – Upload no more than one page of references (**1 page limit, PDF only**)
- **Are you currently/previouisly funded by/collaborated with Takeda?**

No budget is required at this time



Confidentiality

Members of Takeda and Harrington Discovery Institute review panels and the Rare Disease Scientific Advisory Board sign mutual Confidentiality & Disclosure Agreements to protect confidential applicant submissions. Non-public applicant information is always kept confidential (and limited in distribution to the reviewers and Harrington Discovery Institute). The abstract, applicant's name, and institutional affiliation for those selected as Harrington Rare Disease Scholars may be used by Takeda and Harrington Discovery Institute for publicity and marketing purposes (on the Takeda and Harrington Discovery Institute websites, news releases, etc.) at the sole discretion of Takeda and Harrington Discovery Institute.

Intellectual Property

Harrington Discovery Institute and Takeda represent that **Scholar/Institution retain control of patents, copyrights or trademarks to Intellectual Property ("IP")** created as a result of work sponsored by the Harrington Rare Disease Scholar grants.

For questions email: HDIQuestions@HarringtonDiscovery.org

For more information, please visit: HarringtonDiscovery.org/Takeda